Polo-Like Kinase 1 (PLK1) Inhibitor - Pipeline Insight, 2022
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Polo-Like Kinase 1 (PLK1) Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Polo-Like Kinase 1 (PLK1) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Polo-Like Kinase 1 (PLK1) Inhibitor: Overview
Polo-like kinase 1 (Plk1) is a serine/threonine kinase that is a key regulator of multiple stages of mitotic progression. PLK1 is one of the five members of the PLK family and are found in the nuclei of all dividing cells. PLKs are defined by two conserved features: an N terminal Ser/Thr kinase domain and a C-terminal duplicated Polo-box region. PLK1 is the most extensively studied of five members of the polo-like family and is primarily known for operating as a pleiotropic master regulator of the cell cycle from entry into mitosis to the initiation of cytokinesis. This includes regulating the activity of proteins involved in establishing centromeres, initiating spindle checkpoint signaling and coordinating the activity of the spindle checkpoint. PLK1 inhibition has been shown to cause mitotic block and apoptosis of tumor cells. The potential of PLK1 inhibitors as cancer therapeutic has been widely explored, which resulted in several PLK1 inhibitors in clinical trials following their preclinical successes.
Report Highlights
This segment of the Polo-Like Kinase 1 (PLK1) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Polo-Like Kinase 1 (PLK1) Inhibitor Emerging Drugs
Further product details are provided in the report……..
Polo-Like Kinase 1 (PLK1) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Polo-Like Kinase 1 (PLK1) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
Polo-Like Kinase 1 (PLK1) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Polo-Like Kinase 1 (PLK1) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polo-Like Kinase 1 (PLK1) Inhibitor drugs.
Polo-Like Kinase 1 (PLK1) Inhibitor Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Polo-Like Kinase 1 (PLK1) Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Polo-Like Kinase 1 (PLK1) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Polo-Like Kinase 1 (PLK1) Inhibitor: Overview
Polo-like kinase 1 (Plk1) is a serine/threonine kinase that is a key regulator of multiple stages of mitotic progression. PLK1 is one of the five members of the PLK family and are found in the nuclei of all dividing cells. PLKs are defined by two conserved features: an N terminal Ser/Thr kinase domain and a C-terminal duplicated Polo-box region. PLK1 is the most extensively studied of five members of the polo-like family and is primarily known for operating as a pleiotropic master regulator of the cell cycle from entry into mitosis to the initiation of cytokinesis. This includes regulating the activity of proteins involved in establishing centromeres, initiating spindle checkpoint signaling and coordinating the activity of the spindle checkpoint. PLK1 inhibition has been shown to cause mitotic block and apoptosis of tumor cells. The potential of PLK1 inhibitors as cancer therapeutic has been widely explored, which resulted in several PLK1 inhibitors in clinical trials following their preclinical successes.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Polo-Like Kinase 1 (PLK1) Inhibitor R&D. The therapies under development are focused on novel approaches for Polo-Like Kinase 1 (PLK1) Inhibitor.
This segment of the Polo-Like Kinase 1 (PLK1) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Polo-Like Kinase 1 (PLK1) Inhibitor Emerging Drugs
- Onvansertib: Cardiff Oncology
- CYC-140: Cyclacel Pharmaceuticals
Further product details are provided in the report……..
Polo-Like Kinase 1 (PLK1) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Polo-Like Kinase 1 (PLK1) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Polo-Like Kinase 1 (PLK1) Inhibitor
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Polo-Like Kinase 1 (PLK1) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Polo-Like Kinase 1 (PLK1) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polo-Like Kinase 1 (PLK1) Inhibitor drugs.
Polo-Like Kinase 1 (PLK1) Inhibitor Report Insights
- Polo-Like Kinase 1 (PLK1) Inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Polo-Like Kinase 1 (PLK1) Inhibitor drugs?
- How many Polo-Like Kinase 1 (PLK1) Inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Polo-Like Kinase 1 (PLK1) Inhibitor?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Polo-Like Kinase 1 (PLK1) Inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Polo-Like Kinase 1 (PLK1) Inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?
- Oncoheroes Biosciences
- Cyclacel Pharmaceuticals
- Cardiff Oncology
- Onconova Therapeutics
- Sentinel oncology
- Volasertib
- CYC-140
- Onvansertib
- Rigosertib
- SOL686
Introduction
Executive Summary
Polo-Like Kinase 1 (PLK1) Inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Polo-Like Kinase 1 (PLK1) Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Polo-Like Kinase 1 (PLK1) Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Polo-Like Kinase 1 (PLK1) Inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Onvansertib: Cardiff Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CYC-140: Cyclacel Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Volasertib: Oncoheroes Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Polo-Like Kinase 1 (PLK1) Inhibitor Key Companies
Polo-Like Kinase 1 (PLK1) Inhibitor Key Products
Polo-Like Kinase 1 (PLK1) Inhibitor- Unmet Needs
Polo-Like Kinase 1 (PLK1) Inhibitor- Market Drivers and Barriers
Polo-Like Kinase 1 (PLK1) Inhibitor- Future Perspectives and Conclusion
Polo-Like Kinase 1 (PLK1) Inhibitor Analyst Views
Polo-Like Kinase 1 (PLK1) Inhibitor Key Companies
Appendix
Executive Summary
Polo-Like Kinase 1 (PLK1) Inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Polo-Like Kinase 1 (PLK1) Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Polo-Like Kinase 1 (PLK1) Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Polo-Like Kinase 1 (PLK1) Inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Onvansertib: Cardiff Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CYC-140: Cyclacel Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Volasertib: Oncoheroes Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Polo-Like Kinase 1 (PLK1) Inhibitor Key Companies
Polo-Like Kinase 1 (PLK1) Inhibitor Key Products
Polo-Like Kinase 1 (PLK1) Inhibitor- Unmet Needs
Polo-Like Kinase 1 (PLK1) Inhibitor- Market Drivers and Barriers
Polo-Like Kinase 1 (PLK1) Inhibitor- Future Perspectives and Conclusion
Polo-Like Kinase 1 (PLK1) Inhibitor Analyst Views
Polo-Like Kinase 1 (PLK1) Inhibitor Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Polo-Like Kinase 1 (PLK1) Inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Polo-Like Kinase 1 (PLK1) Inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Polo-Like Kinase 1 (PLK1) Inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Polo-Like Kinase 1 (PLK1) Inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products